From a Founder's Vision to Clinically-Proven Results.

Cellionyx was founded on a singular mission: to engineer healing at the cellular level. After seeing the limitations of conventional therapies firsthand, Sanjay assembled a world-class team to build technology that works with the body's intelligence.

About Cellionyx

Mission & Vision

Our Mission

To revolutionize healing through precision bioelectric therapy, transforming how the medical community approaches tissue repair, pain management, and regenerative medicine by engineering solutions that work at the cellular level.

Our Vision

A world where every patient has access to advanced, non-invasive healing technologies that accelerate recovery, reduce pain, and restore function faster than ever thought possible.

Meet the Founder

Sanjay Bagai

Founder & CEO

Sanjay is a seasoned technology entrepreneur with 30+ years of global experience in innovation and venture development. He founded Equstech, where he developed the K2 device—a pioneering non-invasive bioelectric therapeutic tool for equine rehabilitation. His vision for Cellionyx stems from firsthand experience with bioelectric healing technology and a deep understanding of performance recovery needs across both human and veterinary applications.

Expertise: Bioelectric therapeutic technology, medical device development, venture leadership

Previous Ventures: Equstech (veterinary bioelectric devices), technology ventures in ERP/CRM solutions

Background: 30+ years global technology and innovation experience

Vision: Bringing proven bioelectric healing technology from veterinary success to human healthcare

Our Journey

2018

Company Founded

Sanjay establishes Cellionyx with initial seed funding and begins developing core EDCMC technology.

2019

R&D Development

Research and development focused on developing our proprietary wavelength technology and core EDCMC principles.

2020

Proprietary Wavelength Innovation

Continued R&D efforts developing our proprietary wavelength technology for optimal cellular regeneration.

2021

Technology Development

Advanced R&D developing our proprietary wavelength technology with enhanced precision and efficacy.

2022

Testing Phase

Comprehensive testing and validation of Cytomotion™ technology across multiple clinical applications.

2023

Technology Refining

Refining and optimizing the Cytomotion™ device for enhanced performance and clinical outcomes.

2024

Market Launch Preparation

Preparing for commercial launch with manufacturing scale-up and regulatory approval process.

Our Team

World-class expertise across biomedical engineering, clinical research, regulatory affairs, and commercial operations.

25+
Team Members
8
PhD Scientists
150+
Combined Years Experience
6
Clinical Advisors

Engineering & R&D

  • Biomedical Engineering
  • Electrical Engineering
  • Materials Science
  • Software Development
  • Mechanical Engineering
  • Quality Assurance

Clinical & Scientific

  • Cellular Biology
  • Clinical Research
  • Biostatistics
  • Regulatory Affairs
  • Medical Affairs
  • Clinical Operations

Business & Operations

  • Commercial Strategy
  • Marketing & Sales
  • Manufacturing
  • Finance & Administration
  • Legal & IP
  • Human Resources

Ready to Transform Patient Outcomes?

Request a clinical demo to see how Cytomotion™ can integrate into your practice and revolutionize your approach to healing.